Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials, localization and an operational hub overseeing 75 countries. After almost two decades working with the Danish diabetes and obesity giant, he illustrates the crucial role that the company has to play in the country with the highest incidence of diabetes in Europe.
Every crisis creates an opportunity and I believe that COVID showed us the importance of investing in R&D and the pharma sector to bring innovation
